Nigmatullina, Razina R <br/><br/>
Disrupted serotonergic and sympathoadrenal systems in patients with chronic heart failure may serve as new therapeutic targets and novel biomarkers to assess severity, progression and response to treatment.  [electronic resource] 

 -  Cardiology  2009 
 - 277-86 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1421-9751 
<br/><br/><label>Standard No.: </label>10.1159/000205962  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adrenal Glands--physiopathology<br/>Adrenergic beta-Antagonists--therapeutic use<br/>Adult<br/>Biomarkers--blood<br/>Chronic Disease<br/>Dihydroxyphenylalanine--blood<br/>Disease Progression<br/>Dopamine--blood<br/>Epinephrine--blood<br/>Female<br/>Heart Failure--diagnosis<br/>Humans<br/>Hydroxyindoleacetic Acid--blood<br/>Male<br/>Middle Aged<br/>Norepinephrine--blood<br/>Serotonin--blood<br/>Severity of Illness Index<br/>Sympathetic Nervous System--physiopathology